Rivaroxaban: FDA and others [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2022-07-04 15:19 (650 d 22:54 ago) – Posting: # 23104
Views: 1,885

Hi Tricky,

❝ Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?


It depends on the ‘target’ agency. For the FDA and China’s CDE no way because you have to compare the within-subject variability of test and reference. That requires a full replicate design. For details see the warfarin-guidance (ignore the part about reference-scaling; for rivaroxaban the conventional limits of 80.00–125.00% are applicable).

For all other agencies a 2×2×2 likely would do. In the EMA’s product-specific guidance no design is mentioned. However, riva­roxaban may show high variability, esp. in fed state. Be prepared for large sample sizes.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,983 posts in 4,822 threads, 1,648 registered users;
38 visitors (0 registered, 38 guests [including 4 identified bots]).
Forum time: 14:13 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5